Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jingwen Wang(Beijing Tongren Hospital), Xiaoqiong Tang(The Affiliated Yongchuan Hospital of Chongqing Medical University), Qingshu Zeng(Anhui Medical University), Lugui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianqiu Wu(Jiangsu Cancer Hospital), Jianfeng Zhou(Tongji Hospital), Qifa Liu(Nanfang Hospital), Yuqin Song(Peking University), Hongming He(Fujian Provincial Cancer Hospital), Weili Zhao(Shanghai Jiao Tong University), Haiyan Yang(Chinese Academy of Sciences), Mei Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiequn Chen(Northwest University), Jianmin Yang(Canadian Food Inspection Agency), Yi Luo(Hunan Cancer Hospital), Xiuhua Sun(Dalian Medical University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Jingyan Xu(Nanjing Drum Tower Hospital), Jianzhen Shen(Fujian Medical University), Ming Hou(Shandong University), Xin Wang(Shandong University), Peng Liu(Sun Yat-sen University), Xiaoling Li(University of Alabama at Birmingham), Xiaodong Wang(Shandong Provincial Hospital), Wenyu Li(Guangdong Provincial People's Hospital), Ting Liu(Xinqiao Hospital), Lihong Liu(Hebei Medical University), Zhihui Zhang(Anhui Medical University), Zhen Cai(Zhejiang University), Huo Tan(First Affiliated Hospital of Guangzhou Medical University), Wei Xu(Shandong Provincial Hospital), Huaqing Wang(Beijing University of Chemical Technology), Jie Jin(First Affiliated Hospital Zhejiang University), Lin Liu(Hebei Medical University), Bo Jia(Peking University), Jian‐Min Luo(Second Hospital of Hebei Medical University), Huiqiang Huang(Sun Yat-sen University), Zhiming Li(Sun Yat-sen University), Pingyong Yi(Hunan Cancer Hospital), Xiaobing Huang(Sichuan Provincial Hospital of Traditional Chinese Medicine), Liping Su, Yuhuan Gao(Hebei Medical University), Rong Liang(Xijing Hospital), Zimin Sun(Anhui Provincial Hospital), Zhengming Jin(Soochow University), Jinghua Wang(Beijing Tongren Hospital), Kaiyang Ding(Anhui Provincial Hospital), Xi Zhang(Army Medical University), Huilai Zhang(Tianjin Medical University Cancer Institute and Hospital)
Cited by 256
Related Papers
Targeting the Wnt/β-catenin signaling pathway in cancer
|Journal of Hematology & Oncology|2020|1.4k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent
|Journal of Experimental & Clinical Cancer Research|2021|291